EU/3/01/020

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2014 at the end of the period of market exclusivity.

On 14 February 2001, orphan designation (EU/3/01/020) was granted by the European Commission to Orphan Europe, France, for ibuprofen for the treatment of patent ductus arteriosus.

Ibuprofen has been authorised in the EU as Pedea since 29 July 2004.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Ibuprofen
Medicine name
Pedea
Disease / condition
Treatment of patent ductus arteriosus
Date of first decision
15/02/2001
Outcome
Expired
EU designation number
EU/3/01/020

Sponsor's contact details

Orphan Europe SARL
Immeuble Le Wilson
70 Avenue du Général de Gaulle
F-92800 Puteaux
France
Tel. +33 1 4773 6458
Fax +33 1 49 00 18 00
E-mail: info@orphan-europe.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating